$1.43
1.42% yesterday
Nasdaq, May 14, 10:07 pm CET
ISIN
NL0015000DX5
Symbol
ATAI
Sector
Industry

ATAI Life Sciences N.V. Stock price

$1.43
+0.05 3.62% 1M
+0.06 4.38% 6M
+0.10 7.52% YTD
-0.48 25.13% 1Y
-2.61 64.60% 3Y
-18.02 92.65% 5Y
-18.02 92.65% 10Y
Nasdaq, Closing price Wed, May 14 2025
+0.02 1.42%
ISIN
NL0015000DX5
Symbol
ATAI
Sector
Industry

Key metrics

Market capitalization $285.71m
Enterprise Value $209.20m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 633.94
P/S ratio (TTM) P/S ratio 865.79
P/B ratio (TTM) P/B ratio 1.65
Revenue growth (TTM) Revenue growth -0.90%
Revenue (TTM) Revenue $330.00k
EBIT (operating result TTM) EBIT $-105.88m
Free Cash Flow (TTM) Free Cash Flow $-79.86m
Cash position $108.20m
EPS (TTM) EPS $-0.80
P/E forward negative
P/S forward 460.82
EV/Sales forward 337.42
Short interest 7.98%
Show more

Is ATAI Life Sciences N.V. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,785 stocks worldwide.

ATAI Life Sciences N.V. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a ATAI Life Sciences N.V. forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a ATAI Life Sciences N.V. forecast:

Buy
100%

Financial data from ATAI Life Sciences N.V.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
0.33 0.33
0% 0%
100%
- Direct Costs 0.35 0.35
29% 29%
106%
-0.02 -0.02
88% 88%
-6%
- Selling and Administrative Expenses 55 55
7% 7%
16,724%
- Research and Development Expense 50 50
28% 28%
15,248%
-106 -106
18% 18%
-31,979%
- Depreciation and Amortization 0.35 0.35
29% 29%
106%
EBIT (Operating Income) EBIT -106 -106
18% 18%
-32,084%
Net Profit -129 -129
92% 92%
-38,970%

In millions USD.

Don't miss a Thing! We will send you all news about ATAI Life Sciences N.V. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ATAI Life Sciences N.V. Stock News

Positive
Proactive Investors
one day ago
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has kicked off 2025 with strong momentum across its clinical pipeline ahead of expected key data readouts later this year and into 2026. Recent operational highlights include dosing the first patient in a Phase 2 trial of EMP-01 (oral R-MDMA) for social anxiety disorder and continued enrollment in the Elumina study evaluating VLS-01, a buccal film formu...
Neutral
GlobeNewsWire
one day ago
With clinical momentum across its pipeline, atai strengthens its position as a leader in potentially transformative psychedelic mental health treatments
Positive
Proactive Investors
2 days ago
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that it has dosed the first patient in its Phase 2 clinical trial of EMP-01 for the treatment of social anxiety disorder (SAD). EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine, is being investigated in an exploratory, randomized, double-blind, placebo-controlled study involving approximately 60 adult participants with SAD.
More ATAI Life Sciences N.V. News

Company Profile

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Berlin, Germany.

Head office Netherlands
CEO Srinivas Rao
Employees 54
Founded 2018
Website www.atai.life

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today